Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside
In a fast-paced medical reality, biosciences and bioengineering have become essential components in medical research and development. The aim of this paper is to characterize the recent progresses made in fighting antimicrobial resistance, particularly in relation to WHO’s priority pathogens, by pro...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/12/22/11615 |
| _version_ | 1827645101821657088 |
|---|---|
| author | Oana Săndulescu Ioana Viziteu Anca Streinu-Cercel Victor Daniel Miron Liliana Lucia Preoțescu Narcis Chirca Simona Elena Albu Mihai Craiu Adrian Streinu-Cercel |
| author_facet | Oana Săndulescu Ioana Viziteu Anca Streinu-Cercel Victor Daniel Miron Liliana Lucia Preoțescu Narcis Chirca Simona Elena Albu Mihai Craiu Adrian Streinu-Cercel |
| author_sort | Oana Săndulescu |
| collection | DOAJ |
| description | In a fast-paced medical reality, biosciences and bioengineering have become essential components in medical research and development. The aim of this paper is to characterize the recent progresses made in fighting antimicrobial resistance, particularly in relation to WHO’s priority pathogens, by providing an in-depth review of novel antimicrobials, drug delivery systems for targeted antimicrobial action and novel antivirulence targets. We systematically searched the ClinicalTrials.gov database to identify clinical trials targeting WHO’s priority 1 (critical) pathogens: carbapenem-resistant <i>Acinetobacter baumannii</i>, carbapenem-resistant <i>Pseudomonas aeruginosa</i>, and carbapenem-resistant ESBL-producing Enterobacteriaceae. We identified a limited number of clinical trials, specifically for: one novel betalactamase inhibitor for <i>Acinetobacter</i> spp., one anti-virulence human monoclonal antibody for <i>Pseudomonas</i> spp. and no novel antimicrobials for carbapenem-resistant Enterobacteriaceae. We also performed a review of field literature to exemplify the main applications of drug delivery systems in infectious diseases, particularly in achieving targeted antibiotic distribution, in enhancing local activity with reduced off-target effects, triggered antibiotic release and triggered antibacterial photodynamic therapy. We conclude by presenting novel targets for antivirulence therapeutics that act by disrupting quorum sensing, inhibiting bacterial adherence and biofilm formation, silencing virulence traits and neutralizing bacterial toxins. Furthermore, the main principles of rational antimicrobial use are highlighted, in an effort to describe potential areas for targeted intervention, from diagnostic stewardship to antimicrobial stewardship. |
| first_indexed | 2024-03-09T18:29:46Z |
| format | Article |
| id | doaj.art-da24414ab0234e5b88b0599ff40f613b |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-09T18:29:46Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-da24414ab0234e5b88b0599ff40f613b2023-11-24T07:38:08ZengMDPI AGApplied Sciences2076-34172022-11-0112221161510.3390/app122211615Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to BedsideOana Săndulescu0Ioana Viziteu1Anca Streinu-Cercel2Victor Daniel Miron3Liliana Lucia Preoțescu4Narcis Chirca5Simona Elena Albu6Mihai Craiu7Adrian Streinu-Cercel8Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaFaculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, RomaniaIn a fast-paced medical reality, biosciences and bioengineering have become essential components in medical research and development. The aim of this paper is to characterize the recent progresses made in fighting antimicrobial resistance, particularly in relation to WHO’s priority pathogens, by providing an in-depth review of novel antimicrobials, drug delivery systems for targeted antimicrobial action and novel antivirulence targets. We systematically searched the ClinicalTrials.gov database to identify clinical trials targeting WHO’s priority 1 (critical) pathogens: carbapenem-resistant <i>Acinetobacter baumannii</i>, carbapenem-resistant <i>Pseudomonas aeruginosa</i>, and carbapenem-resistant ESBL-producing Enterobacteriaceae. We identified a limited number of clinical trials, specifically for: one novel betalactamase inhibitor for <i>Acinetobacter</i> spp., one anti-virulence human monoclonal antibody for <i>Pseudomonas</i> spp. and no novel antimicrobials for carbapenem-resistant Enterobacteriaceae. We also performed a review of field literature to exemplify the main applications of drug delivery systems in infectious diseases, particularly in achieving targeted antibiotic distribution, in enhancing local activity with reduced off-target effects, triggered antibiotic release and triggered antibacterial photodynamic therapy. We conclude by presenting novel targets for antivirulence therapeutics that act by disrupting quorum sensing, inhibiting bacterial adherence and biofilm formation, silencing virulence traits and neutralizing bacterial toxins. Furthermore, the main principles of rational antimicrobial use are highlighted, in an effort to describe potential areas for targeted intervention, from diagnostic stewardship to antimicrobial stewardship.https://www.mdpi.com/2076-3417/12/22/11615antimicrobialantivirulenceresistancedrug deliverystewardship |
| spellingShingle | Oana Săndulescu Ioana Viziteu Anca Streinu-Cercel Victor Daniel Miron Liliana Lucia Preoțescu Narcis Chirca Simona Elena Albu Mihai Craiu Adrian Streinu-Cercel Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside Applied Sciences antimicrobial antivirulence resistance drug delivery stewardship |
| title | Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside |
| title_full | Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside |
| title_fullStr | Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside |
| title_full_unstemmed | Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside |
| title_short | Novel Antimicrobials, Drug Delivery Systems and Antivirulence Targets in the Pipeline—From Bench to Bedside |
| title_sort | novel antimicrobials drug delivery systems and antivirulence targets in the pipeline from bench to bedside |
| topic | antimicrobial antivirulence resistance drug delivery stewardship |
| url | https://www.mdpi.com/2076-3417/12/22/11615 |
| work_keys_str_mv | AT oanasandulescu novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT ioanaviziteu novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT ancastreinucercel novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT victordanielmiron novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT lilianaluciapreotescu novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT narcischirca novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT simonaelenaalbu novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT mihaicraiu novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside AT adrianstreinucercel novelantimicrobialsdrugdeliverysystemsandantivirulencetargetsinthepipelinefrombenchtobedside |